141 related articles for article (PubMed ID: 23924445)
1. Controversy of the prostate-specific antigen test era: should prostate cancer be detected and treated in all patients?
Zhang N; Zhang XD
Chin Med J (Engl); 2013; 126(15):2803-4. PubMed ID: 23924445
[No Abstract] [Full Text] [Related]
2. Prostate cancer: Personalized risk - stratified screening or abandoning it altogether?
Carlsson SV; Kattan MW
Nat Rev Clin Oncol; 2016 Mar; 13(3):140-2. PubMed ID: 26831183
[No Abstract] [Full Text] [Related]
3. Successful separation between benign prostatic hyperplasia and prostate cancer by measurement of free and complexed PSA.
Lilja H; Stenman UH
Cancer Treat Res; 1996; 88():93-101. PubMed ID: 9239474
[No Abstract] [Full Text] [Related]
4. Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?
Faiena I; Holden S; Cooperberg MR; Holden S; Soule HR; Simons JW; Morgan TM; Penson DF; Morgans AK; Hussain M
J Clin Oncol; 2018 Apr; 36(10):937-941. PubMed ID: 29401003
[No Abstract] [Full Text] [Related]
5. Prostate-specific antigen (hK3) and human prostatic glandular kallikrein (hK2) in the detection of early stage human prostate cancer.
Wilson MJ
J Lab Clin Med; 1998 Apr; 131(4):298-9. PubMed ID: 9579381
[No Abstract] [Full Text] [Related]
6. Prostate-specific antigen or human kallikrein 3? Recent developments.
Diamandis EP
Tumour Biol; 1998; 19(2):65-7; discussion 67-8. PubMed ID: 9486557
[No Abstract] [Full Text] [Related]
7. Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly.
Hu JC; Williams SB; Carter SC; Eggener SE; Prasad S; Chamie K; Trinh QD; Sun M; Nguyen PL; Lipsitz SR
Urol Oncol; 2015 Feb; 33(2):69.e29-34. PubMed ID: 25017694
[TBL] [Abstract][Full Text] [Related]
8. Purification of a Human Prostate Specific Antigen.
Wang MC; Valenzuela LA; Murphy GP; Chu TM
J Urol; 2017 Feb; 197(2S):S148-S152. PubMed ID: 28012750
[TBL] [Abstract][Full Text] [Related]
9. Sarcomatoid carcinoma of the prostate with adenocarcinoma, squamous cell carcinoma, and heterologous components.
Acosta AM; Senseng C; Kim G; Sekosan M; Ree N
APMIS; 2016 Aug; 124(8):719-22. PubMed ID: 27197712
[No Abstract] [Full Text] [Related]
10. Prostate detection possibility.
Gunby P
JAMA; 1999 Jun 23-30; 281(24):2274-5. PubMed ID: 10386541
[No Abstract] [Full Text] [Related]
11. Time trends in prostate cancer screening in Swiss primary care (2010 to 2017) - A retrospective study.
Zechmann S; Di Gangi S; Kaplan V; Meier R; Rosemann T; Valeri F; Senn O;
PLoS One; 2019; 14(6):e0217879. PubMed ID: 31194773
[TBL] [Abstract][Full Text] [Related]
12. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
Vickers AJ; Cronin AM; Aus G; Pihl CG; Becker C; Pettersson K; Scardino PT; Hugosson J; Lilja H
Cancer; 2010 Jun; 116(11):2612-20. PubMed ID: 20336781
[TBL] [Abstract][Full Text] [Related]
13. Value of a Statistical Model Based on Four Kallikrein Markers in Blood, Commercially Available as 4Kscore, in All Reasonable Prostate Biopsy Subgroups.
Vickers AJ; Vertosick EA; Sjoberg DD
Eur Urol; 2018 Oct; 74(4):535-536. PubMed ID: 29903434
[No Abstract] [Full Text] [Related]
14. Nonpalpable prostate cancer detected in the prostate-specific antigen era.
Carter HB
World J Urol; 1997; 15(6):329-30. PubMed ID: 9436280
[No Abstract] [Full Text] [Related]
15. Impact of health literacy on shared decision making for prostate-specific antigen screening in the United States.
Nguyen DD; Trinh QD; Cole AP; Kilbridge KL; Mahal BA; Hayn M; Hansen M; Han PKJ; Sammon JD
Cancer; 2021 Jan; 127(2):249-256. PubMed ID: 33165954
[TBL] [Abstract][Full Text] [Related]
16. Summary statement on screening for prostate cancer in Europe.
Heijnsdijk EAM; Bangma CH; Borràs JM; de Carvalho TM; Castells X; Eklund M; Espinàs JA; Graefen M; Grönberg H; Lansdorp-Vogelaar I; Leeuwen PJV; Nelen V; Recker F; Roobol MJ; Vandenbulcke P; de Koning HJ
Int J Cancer; 2018 Feb; 142(4):741-746. PubMed ID: 29023685
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and Prognostic Factors in 106 Prostate Cancer Patients Aged ≤55 Years: A Single-Center Study in China.
Xu Y; Yang X; Si T; Yu H; Zhang W; Li Y; Guo Z
Med Sci Monit; 2016 Oct; 22():3935-3942. PubMed ID: 27771734
[TBL] [Abstract][Full Text] [Related]
18. Issues in the assessment of prostate-specific antigen immunoassays. An update.
Vessella RL; Lange PH
Urol Clin North Am; 1997 May; 24(2):261-8. PubMed ID: 9126222
[TBL] [Abstract][Full Text] [Related]
19. Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancer.
Lindberg A; Talala K; Kujala P; Stenman UH; Taari K; Kilpeläinen TP; Tammela TL; Auvinen A
Int J Cancer; 2019 Aug; 145(3):632-638. PubMed ID: 30653262
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen: what's new in 1997.
Pannek J; Partin AW
Oncology (Williston Park); 1997 Sep; 11(9):1273-8; discussion 1279-82. PubMed ID: 9306417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
